CELSUS THERAPEUTICS STRENGTHENS BOARD OF DIRECTORS WITH ADDITION OF DERMATOLOGY INDUSTRY VETERAN ROBERT F. DOMAN NEW YORK

CELSUS THERAPEUTICS STRENGTHENS BOARD

ADDITION OF DERMATOLOGY INDUSTRY VETERAN ROBERT F. DOMAN

NEW YORK, NY AND LONDON, UK - May 1, 2013 -

Celsus Therapeutics (OTCQB: MRRBY), an emerging growth, development-stage biotech company, announced the addition of industry veteran

Robert F. Doman to the Company's Board of Directors.

"We are pleased that Bob has joined our board of directors,"

said Gur Roshwalb, Chief Executive Officer of Celsus Therapeutics. "He brings more than 30 years of international and domestic

pharmaceutical and medical leadership to the board, especially in the field of dermatology, the focus of our lead asset in Phase

II trials, MRX-6. His business development, strategic planning and dermatology product development skills will be valuable assets

as we continue to advance our portfolio of non-steroidal anti-inflammatory drugs."

"I am pleased to be joining

the Celsus board where I will have the opportunity to work closely with management and the other board members to create shareholder

value," said Mr. Doman. "I look forward to quickly

contributing to the next stage in Celsus' growth by helping to direct development of MRX-6 and advancing the current pipeline

of promising anti-inflammatory drugs."

Mr. Doman is a seasoned pharmaceutical and medical device executive

with 30+ years of extensive international and domestic experience in general management, business development, building sales and

marketing capabilities, new product development and strategic planning. Most recently Bob served as President and Chief Executive

Officer of DUSA Pharmaceuticals, Inc., a publicly traded specialty pharmaceutical and medical device company focused in the field

of dermatology. He joined DUSA in 2005 as President and Chief Operating Officer and was promoted to President and Chief Executive

Officer in June 2007. DUSA was acquired by Sun Pharma in June of 2012. Prior to joining DUSA

Pharmaceuticals, Bob served as President of Leach Technology Group, the medical electronic device, design, product development

and contract manufacturing services division of privately held Leach Holding Corporation. From 1999 to 2000, Bob served as President,

Device Product Development of West Pharmaceutical Services, a manufacturer of systems and device components for parentally administered

medicines and drugs. From 1991 to 1999, Bob worked for the Convatec division of Bristol-Myers Squibb in positions that included:

Vice President, Worldwide Marketing and Business Development; Vice President and General Manager, U.S. Wound and Skin Care; and

Vice President, U.S. Operations.

Earlier in his career, Bob held sales, marketing and business

development roles of increasing responsibilities for Critikon, Inc., a Johnson and Johnson company. While serving as Business Director

for Vascular Access he licensed and launched the first Intravenous Catheter with needle-stick protection, which is the industry

standard today. Bob currently serves as a member of the Board of Directors of Echo Therapeutics, Inc.

(NASDAQ: ECTE). He received a Bachelor's degree from Saint Joseph's University where he has served as a member

of the Development Committee and the Haub School of Business Advisory Board.

About Celsus Therapeutics Plc.

Celsus Therapeutics is an

emerging clinical stage company focused on the development of a new class of non-steroidal, synthetic anti-inflammatory drugs termed

Multi-Functional Anti-Inflammatory Drugs or MFAIDs. Celsus's MFAIDs represent a new therapeutic platform for the treatment

of a broad array of inflammatory diseases, such as allergies and autoimmune diseases. Presently, the Company has two lead drug

candidates in its clinical pipeline, MRX-6, a topical cream for contact dermatitis and MRX-4, a nasal spray for treating allergic

rhinitis (hay fever). Other potential treatments in preclinical development include OPX-1 for ocular inflammation, CFX-1 for cystic

fibrosis, and MRX-5 for inflammatory bowel disease.

FORWARD-LOOKING STATEMENTS - This press release contains

"forward-looking statements" that involve known and unknown risks, uncertainties and other factors that may cause our

actual results, performance or achievements to be materially different from any future results, performance or achievements expressed

or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms including "anticipates,"

"believes," "could," "estimates," "expects," "intends," "may," "plans,"

"potential," "predicts," "projects," "should," "will," "would," "hope,"

"look forward" and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect

our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. You should

not put undue reliance on any forward-looking statements. Unless we are required to do so under applicable laws, we do not intend

to update or revise any forward-looking statements.